23.05.2018 • NewsClariantElaine BurridgeSABIC

SABIC Selects SD’s EO/EG Technology

SABIC Selects SD’s EO/EG Technology (c) Sabic
SABIC Selects SD’s EO/EG Technology (c) Sabic

Saudi petrochemicals and plastics group SABIC has selected ethylene oxide/ethylene glycol (EO/EG) technology from Scientific Design (SD) for a 700,000 EG plant in Al Jubail. The plant will be the eighth EO/EG facility that SD has licensed to SABIC. The company is jointly owned by SABIC and Swiss specialty chemicals company Clariant.

The contract includes the process technology license, a process design package, technical assistance and start-up services and the initial charge of SD’s EO catalyst. A timescale for the project was not disclosed.

SABIC previously chose SD to provide the process design package, technical assistance and start-up services for an expansion of Saudi Kayan’s EO/EG plant, also located in Al Jubail, and Yansab’s EG plant in Yanbu. Both Saudi Kayan and Yansab are affiliates of SABIC.

The Saudi Kayan plant has been operating at its expanded capacity since last November. The expansion at Yansab is expected to be completed by mid-2018.

 

 

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.